Therapy for relapsed/refractory sickness should be determined according to prior therapy as well as The main reason why the original cure was not acceptable (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold standard therapy for patients with relapsed/refractory disease, determined by the outcome of several phase I-III trials, a